KRAS and neoplasm: In addition, DDX3X promotes KRAS-dependent tumor invasion by activating the β-catenin/ZEB1 pathway that requires β-catenin/TCF4 activation by DDX3X through the Wnt/CK1ε/Dvl2 axis [24].